Use our interactive tool to explore the wealth of content within Clarivate Analytics' products that help drive immuno-oncology research and drug discovery. Click on the content badges below to explore and gain insight into how our products and data can support researchers and scientists to drive innovation in Immuno-oncology.

Web of Science

Volumes (updated at October 2016) : 636,544 oncology records

Web of Science is a comprehensive research platform. Journal articles, patents, websites, conference proceedings, Open Access material—all can be accessed through one interface, using a variety of powerful search and analysis tools. Web of Science Core Collection is a painstakingly selected, actively curated database of the journals that researchers themselves have judged to be the most important and useful in their fields. With Web of Science, over 7,000 academic and research institutions, national governments, funding organizations, and publishing organizations around the world are finding new connections in research every day.



Preclinical (Integrity)

Volumes: 59850 records

57808 preclinical pharmacology results and 2042 animal models

Hard data points that provide key information from in vitro and in vivo pharmacological assays that delineate drug/receptor and enzyme/target cell interactions. Best collection of animal models to use and evaluate models used in competitor drug development


Compounds with biological activity

Integrity Compounds (BT and PC)

Values: 4,455 compounds with demonstrated biological activity

By integrating biological, chemical and pharmacological data on more than 490,000 compounds with demonstrated biological activity, Integrity provides a unique knowledge solution designed to empower discovery and development activities.



Volumes: Omics, manually curated information including over 1,500 interactions

1611 interactions + 1437 Network objects

MetaCore and KPA are intutive tools for Omics research that can accelerate the gene expression research. MetaCore is an integrated software suite for functional analysis of Next Generation Sequencing, gene expression, CNV, metabolic, proteomics, microRNA, and screening data. MetaCore is based on a high-quality, manually-curated database of molecular interactions, molecular pathways, gene-disease associations, chemical metabolism and toxicity information.

Another product for OMICS analysis is Key Pathway Advisor (KPA). This is a one-click user-friendly workflow tool that lets you quickly upload and get a comprehensive interpretation of gene expression data. Both products are pathway analysis tool for functional analysis of omics data. The underlying manually curated database captures high quality experimental evidence from peer reviewed literature. Through curating interactions, omics-disease relationships, and constructing canonical pathways from these omics experiments allows one to put high dimensional data into a systems biology context.



Volumes (updated at October 2016) : 6683 companies

Pharmaceutical companies protect their products by patenting. A Pharma company's portfolio demonstrates where the company is investing their research activities, and which areas of R&D may have the most and least potential. The exclusivity of a patent lasts for 20 years from filing date, which gives the patent owner a relatively short window of opportunity in what can be a lengthy R&D cycle to develop and commercialise a product before a generic version can be developed.

Our in-depth coverage of Pharmaceutical companies patent portfolios allows for careful monitoring of claims, patent types and the time available before a patent expires.


Biological sequences

Biological sequences (Geneseq)

Volumes: 317,215 biological sequences

GENESEQ is the world's largest source of biological sequences in patents.

GENESEQ is a comprehensive source of manually curated information on patented biological sequences from the first member of the patent family from 47 issuing authorities. GENESEQ provides a new record for each nucleic acid and protein sequence in a patent with patent coverage from 1981. Each GENESEQ entry contains extensive annotations describing the sequence and its commercial application.

Manual curation creates value added insights, such as patent title, record title, abstract and keywords to allow users to understand the context of the sequence quickly. Manual capture of non-electronically available sequences means information is comprehensive, preventing costly mistakes in assessing patent landscape.

Typical subscribers to the GENESEQ database are Intellectual property professionals in biopharma, agrobiotech, diagnostics and consumer goods, patent assessors at national patent authorities and R&D professionals looking for quick insight into what is known about the utility of a sequence and the high level competitive landscape. GENESEQ data is used for a variety of activities including identifying freedom to operate from internal biological innovation, defining patent strategy for internal innovation, monitoring patenting activity of competitors as an early indicator of strategic direction and assessing uniqueness of innovation for patent granting purposes.


News Intelligence


BioWorld Today, which delivers daily actionable intelligence on the most innovative drug development science that drives the business, which funds the means to heal disease, has been tracking the advancement of immuno-oncology (I-O) drugs for more than two decades. With more than 5K I-O articles produced, BioWorld seeks to provide a broad view of drug development, with daily news coverage including:

  • Therapeutic product development from early to late stage
  • Strategic alliances, mergers and acquisitions
  • Corporate financings, both public and private
  • Biopharma company advancements and setbacks
  • Scientific milestones
  • Global regulatory updates
  • Profiles of new and drug development innovators

Thomson Reuters Drug News

Volumes: 4474 news stories

News covering all advances in immuno-oncology research from multiple sources (patents, conferences, scientific literature, company communications). Delivered as daily email alerts and a searchable online archive with 4000+ reports on cancer immunotherapy



Integrity Targets

Volumes: Information on over 656 targets

656 Target records (genes and/or proteins) 43 targetscapes, 11 animations, 15 figures

Target information is key to understanding how an active small molecule compound or biological interacts at a target in the body resulting in an affect which can be beneficial in treating a disease, or detrimental if an adverse reaction occurs. In the battle to developing successful drugs as quickly as possible an understanding of the interaction with a target can help to eliminate any drugs that may fail to have the desired affect.

Resource Resource


Drugs of the Future

11 articles published 2015-2016

Peer-reviewed articles highlighting therapeutic approaches for the treatment of diseases, compounds under development and those in clinical use. Drug monographs contain comprehensive product information on new compounds in development, including synthesis, preclinical pharmacology, pharmacokinetics and metabolism, safety, clinical studies and drug interactions.

Drugs of today

5 articles published 2015-2016

Peer-reviewed articles highlighting the latest developments in the diagnosis and treatment of human diseases, as well as biomarkers for diagnosing diseases, monitoring treatment response, predicting toxicity and identifying candidates for targeted therapy. Drug monographs provide up-to-date reviews on recently approved and launched drugs.

Drug Data Report Abstracts

Volumes 281

Short monographs that provide essential information on drugs and biologics under biological testing, preclinical or clinical development. Content is based on new patents and/or recent literature/congresses. Summaries include most relevant pharmacological and clinical data for a selected lead compound.

Patent Records

Cortellis Patent Records

Volumes: 20,111 indexed citations

Pharmaceutical companies protect their products by patenting. A Pharma company's portfolio demonstrates where the company is investing their research activities, and which areas of R&D may have the most and least potential. The exclusivity of a patent lasts for 20 years from filing date, which gives the patent owner a relatively short window of opportunity in what can be a lengthy R&D cycle to develop and commercialise a product before a generic version can be developed.

Our in-depth coverage of Pharmaceutical companies patent portfolios allows for careful monitoring of claims, patent types and the time available before a patent expires.


Clinical Trials

Cortellis Clinical Trials Intelligence (CTI)

Value 18899

Cortellis Clinical Trials Intelligence (CTI) is a powerful resource to accelerate clinical trial development decisions and portfolio strategy. It features more than 250.000 trial records with approximately 60.000 records related to the oncology field, including Phase 0-4, sourced globally, spanning all countries and all therapeutic areas without limitation.

CTI features clinical information from 25 international trial registries, press releases, literature articles, conference abstracts and reports, company websites, and more. Information from these multiple sources is consolidated into unique trial records that are updated dynamically every day. CTI leverages powerful indexes to explore disease therapy areas, actions and drug classes, when a trial is commercially relevant, when interventions go into a therapy area for the first time, patient segment and eligibility criteria, endpoints, biomarkers, combination therapies, trial designs, and adverse events. CTI provides intelligence about trials locations and clinical investigators. Specifically for the oncology therapeutic area gene variants are indexed within our proprietary patient segmentation indexes.



Integrity BMKs

Volumes: Over 3000 biomarkers use records from over 42,000 distinct biomarkers

A biomarker is a measurable indicator of a biological state or condition and are used to examine the performance of a drug in treating a disease. Researchers continue to seek biomarkers that can accurately support R&D activities (drug development and assay design). Biomarkers can be genomic, proteomic, biochemical or cellular, and go hand-in-hand with our target information. Our content demonstrates where a specific biomarker has been used successfully in research, and may be of use in a new R&D program


Derwent Drug File

Volumes (updated at October 2016) : 29000 refs

Derwent Drug File (DDF) is the definitive source for information on all aspects of drug development, synthesis, evaluation, manufacture and use. It provides references from the worldwide pharmaceutical literature going back to 1964.


Drugs of Today


Drug Records

Cortellis Commercial Drugs

Volumes: 4,418 drug records

Cortellis Forecast Drugs

Volumes: 427 vaccines (included in commerical drugs)

There are over 65,000 unique commercial drug records in various stages of development from preclinical to approved phase, of which 4418 have an immuno-oncological use and are in phase 1 clinical trials and above. The drug record reports in Cortellis CI provide details of current and historical research and development of the drug for a particular indication(s).

Actual and forecasted sales figures are available for specific drugs deemed to have greatest marketing and sales potential, and SWOT analysis demonstrate the value against competitor drugs used for the same indication. The value of this content is in providing competitive intelligence and in easier navigation through huge volumes of data because the drug records are accurately indexed and information is updated in a timely manner


Disease/ epidemiological records


Volumes: 1823 Records

Content for these volumes is based on the cancer epidemiology literature. IPD presents summary reports focusing on incidence, prevalence, and mortality, including tabular data and text.


Disease briefings

23 Cancer Disease Briefing titles; each includes a detailed treatment section on cancer immunotherapy or immuno-oncology

Comprehensive, dynamically updated disease reports covering key disease facts (pathophysiology, risk factors, epidemiology, morbidity and mortality, cost) and a continuously updated text supported by images, multimedia presentations and tables – updated daily – depicting the current competitive landscape of marketed and investigational drugs for the disease. Disease Briefings provide links to additional information such as detailed drug records (including chemical structures) supported by preclinical and clinical studies, as well as links to related clinical guidelines, latest headlines, and Pubmed abstracts for reference citations.


Genetic Variants


Values: Over 1,000 biomarkers use records from over 42,000 distinct biomarkers.

More than 170,000 variant association records and 990,000 gene association records linked to disease and drug response phenotypes, coupled with rich indexing and manual curation to empower a computational pipeline that identifies the key variants based on known phenotypic effect